Use Able AI chat for product recommendations

CDNF Polyclonal antibody, PBS Only

CDNF Polyclonal Antibody for WB, IHC, Indirect ELISA

Cat No. 25035-1-PBS

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, Indirect ELISA

ARMETL1, ARMET like protein 1, ARMET-like protein 1

Formulation:  PBS Only
Conjugate:  Unconjugated
Size/Concentration: 

-/ -

Freight/Packing: -

Quantity

Please visit your regions distributor:


Product Information

25035-1-PBS targets CDNF in WB, IHC, Indirect ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen

CatNo: Ag18972

Product name: Recombinant human ARMETL1 protein

Source: e coli.-derived, PET28a

Tag: 6*His

Domain: 103-187 aa of BC133042

Sequence: MSVHMPAMKICEKLKKLDSQICELKYEKTLDLASVDLRKMRVAELKQILHSWGEECRACAEKTDYVNLIQELAPKYAATHPKTEL

Predict reactive species
Full Name arginine-rich, mutated in early stage tumors-like 1
Calculated Molecular Weight 187 aa, 21 kDa
Observed Molecular Weight 21 kDa
GenBank Accession NumberBC133042
Gene Symbol ARMETL1
Gene ID (NCBI) 441549
RRIDAB_2879861
Conjugate Unconjugated
FormLiquid
Purification MethodAntigen affinity purification
UNIPROT IDQ49AH0
Storage Buffer PBS only, pH 7.3.
Storage ConditionsStore at -80°C.

Background Information

Cerebral dopamine neurotrophic factor (CDNF) is a secreted protein belonging to the mesencephalic astrocyte-derived neurotrophic factor (MANF) family. Unlike classical neurotrophic factors, CDNF is primarily localized in the endoplasmic reticulum and exerts neuroprotective effects through modulating the unfolded protein response (UPR). CDNF has demonstrated potent protective effects on dopaminergic neurons in preclinical models of Parkinson's disease (PD), reducing neuroinflammation and alpha-synuclein aggregation. Its unique mechanism-targeting ER stress rather than receptor tyrosine kinases-offers a promising therapeutic avenue for neurodegenerative disorders. Clinical trials are currently evaluating recombinant human CDNF as a disease-modifying therapy for PD (PMID: 34284712; 37555005; 38290651).

Loading...
||
New chat

Able

正在加载,请稍候...